Similarly, a substantial proportion of cancer patients treated with immune checkpoint inhibitors (ICI) develop immune-related adverse events (irAE), with a reported incidence of ~ 20% of high grade irAE for anti-PD1 treatment and of ~ 60% for the combination of anti-PD1 and anti-CTLA4 [20]. This evidence concerns the gene CTLA4 and cancer.